Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MAGE-10.A2 peptide vaccine
- Development stage
- Unknown
- Lead developer
- Cliniques universitaires Saint-Luc
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous
01
Overview
MAGE-10.A2 peptide vaccine is a synthetic peptide-based cancer vaccine developed by Cliniques Universitaires Saint-Luc (Université Catholique de Louvain) in Brussels, Belgium. It consists of a synthetic HLA-A2-restricted peptide derived from the Melanoma-Associated Antigen 10 (MAGE-10) cancer-testis antigen. The vaccine is designed to stimulate CD8+ cytotoxic T-lymphocyte (CTL) anti-tumor immunity by targeting the MAGE-10 antigen presented via HLA-A2 MHC class I molecules. In clinical trials, such as the Phase 2 trial NCT00365937, it has been evaluated as part of a multipeptide vaccine mix (alongside other melanoma-associated peptides like MAGE-1.A2, MAGE-3.A2, MAGE-4.A2, MAGE-C2.A2, NA17.A2, Tyrosinase.A2, and NY-ESO-1.A2) administered with adjuvants like Montanide ISA 51, IMP321, or CpG 7909 for the treatment of disease-free, HLA-A2-positive cutaneous melanoma patients at high risk of relapse.
- Other names
- MAGE-10.A2 peptideMAGE10.A2 peptideMAGE 10.A2 peptideMAGE-10.A2MAGE10.A2MAGE 10.A2
02
Targets
MAGE-A10-HLA-A2 (Melanoma-associated antigen 10 (MAGE-A10) peptide-human leukocyte antigen A2 (HLA-A2) complex)HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)
Beyond the preview
Go deeper on MAGE-10.A2 peptide vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAGE-10.A2 peptide vaccine.